Publication
Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC.
Andrea Schaefer-Schuler, Arne Blickle, Sebastian Ganz, Sven Petto, Caroline Burgard, Tilman Speicher, Moritz B Bastian, Stephan Maus, Mark Bartholomä, Samer Ezziddin, Florian Rosar
- Source
- PubMed
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260909-000004
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: Terbium-161 (161Tb) has emerged as a promising radionuclide for radioligand therapy (RLT) due to its emission of Auger and conversion electrons, which may support therapeutic efficacy through increased local energy deposition. Despite growing research efforts aimed at the clinical…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04833517registry_reference1.00
Registered trialsNCT04833517
Curated evidence
Evidence citing this paper (0)
Data not yet available